1,102 trials (keyword fallback)
Leukemia
Primary: Percentage of Participants With Overall Response Rate (ORR) — 59.6 Percentage of participants — p=<0.001
Systemic Mastocytosis, Aggressive (ASM) · Leukemia, Mast Cell · Hematological Non-mast Cell Lineage Disease (AHNMD)
Primary: Subjects With Clinical Response [Partial Response (PR) + Complete Response (CR)] — 25 participants
Advanced Systemic Mastocytosis · Aggressive Systemic Mastocytosis · Systemic Mastocytosis With an Associated Hematologic Neoplasm
Primary: Overall Response Rate (ORR) Based on Modified International Working Group-Myeloproliferative Neoplasms Research and Treatment and European Competence Network on…
Systemic Sclerosis
Primary: Improvement in the Modified Rodnan Skin Score — -6.6 units on a scale
Indolent Systemic Mastocytosis
Primary: Percent Change in Quality of Life (QoL) Using Mastocytosis Quality of Life Questionnaire (MC-QoL) — 38.98; 33.02 percentage of change in quality of life — p=0.7740
Systemic Mastocytosis
Primary: Number of Participants With Objective Response — 0 Participants
Aggressive Systemic Mastocytosis · Mast Cell Leukemia · Systemic Mastocytosis
Primary: Overall Response Rate (ORR) Per Consensus International Response Criteria (Rate of Complete or Partial Remissions or Clinical Improvement) — 0 participants
Chronic Myelomonocytic Leukemia · Chronic Myeloid Leukemia · Polycythemia Vera
Primary: Number of Participants With a Complete Response (CR) — 0; 0; 2; 0 participants
Coronary Disease · Cardiovascular Diseases · Heart Diseases
Primary: Number of Participants With All-Cause Mortality — 80; 75; 80; 81 participants — p=0.97
Antisocial Behavior · Aggression
Primary: Change in Antisocial Behavior Inclinations at 24 Hours — 1.41; 3.05 score on a scale
Systemic Sclerosis · Scleroderma
Primary: The Benefit That an Antifibrotic Agent and Ambrisentan Combination Have on the Cutaneous Involvement of Patients With Early Diffuse Systemic Sclerosis by Utilizing the…
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Prolymphocytic Leukemia · Recurrent Adult Diffuse Large Cell Lymphoma · Recurrent Mantle Cell Lymphoma
Primary: Maximum Tolerated Dose for Selinexor — 40 mg
Desmoid Tumors · Aggressive Fibromatosis
Primary: Number of Participants With a Complete Response (CR) + Partial Response (PR) — 0; 5; 1; 11 Participants
Prostate Cancer
Primary: Percentage Change of Phospho-IGF-1R Positive Tumour Cells Following Treatment With Xentuzumab — -8.28 Percentage change Phospho-IGF-1R+ cells